Research Toward a Cure Trials
The October update of this listing of clinical trials and observational studies related to the research effort to cure HIV infection, mainly derived from the clinicaltrials.gov online registry.
Debt and Its Impacts on TB and HIV Investment
Public financing and domestic resources for health are straining under debt burdens as countries struggle to build up domestic revenues in the face of weak tax systems and volatile markets.
Monday, Nov 17, 6:30 pm: 29th Annual Jonathan Lax Memorial Lecture at The Wistar Institute Honors Richard Jefferys
On Monday, Nov. 17th at 6:30 pm EST, Richard Jefferys, Basic Science, Vaccines and Cure Project director at the Treatment Action Group (TAG), delivers the 29th annual Jonathan Lax Memorial Lecture at The Wistar Institute in recognition of his outstanding contributions to HIV research, education and advocacy.
TAG Profoundly Disappointed and Outraged at Lack of Healthcare Protections
Treatment Action Group (TAG) is profoundly disappointed and outraged at the lack of healthcare protections for people living with and affected by HIV, tuberculosis (TB), and hepatitis C (HCV) in the bill to end the US government shutdown.
Open Letter to Canadian PM Mark Carney and Foreign Affairs Minister Anita Anand
TAG signed onto this letter sponsored by the HIV Legal Network to Canadian Prime Minister Mark Carney about the importance of strong investments in health and community systems as they reinforce global health security, which in turn keeps everyone safe.
TAG’s Recommendations to NIAID on the Future of the HIV Clinical Trials Networks
In March 2025, the National Institute of Allergy and Infectious Diseases (NIAID) began soliciting comments on the future of the four Division of AIDS (DAIDS)-sponsored HIV clinical research networks: ACTG, IMPAACT, HPTN, and HVTN.
TAG and ANEA Coalition Condemn Proposed $2 Billion in Cuts to HIV Funding
Treatment Action Group and ANEA Coalition strongly condemn the House Labor, Health and Human Services proposed $2 billion in federal cuts to domestic HIV programs, including plans that would dismantle the CDC’s Division of HIV Prevention and slash $535 million from the Ryan White HIV/AIDS Program.
Joint Statement: Activists Demand $40-a-Year Generic Price for Breakthrough HIV Prevention Drug Be Made Available to All Low- and Middle Income Countries
A global coalition reacted to two deals announced today to make long acting lenacapavir (LEN-LA), a 6 monthly HIV PrEP (pre-exposure prophylaxis) injection that provides virtually 100% protection against HIV infection, at $40 per person per year in 2027.
24 Hours to Save AIDS Research
On September 16 at 11 am (U.S.) savesaidsresearch.org starts a massive marathon to save AIDS funding.
2025 Pipeline Report
Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).